These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34169114)

  • 1. Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines.
    Wee EG; Moyo N; Hannoun Z; Giorgi EE; Korber B; Hanke T
    Mol Ther Methods Clin Dev; 2021 Jun; 21():741-753. PubMed ID: 34169114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
    Mothe B; Manzardo C; Sanchez-Bernabeu A; Coll P; Morón-López S; Puertas MC; Rosas-Umbert M; Cobarsi P; Escrig R; Perez-Alvarez N; Ruiz I; Rovira C; Meulbroek M; Crook A; Borthwick N; Wee EG; Yang H; Miró JM; Dorrell L; Clotet B; Martinez-Picado J; Brander C; Hanke T
    EClinicalMedicine; 2019; 11():65-80. PubMed ID: 31312806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa.
    Beavis AC; Wee EG; Akis Yildirim BM; Borthwick N; He B; Hanke T
    Front Immunol; 2023; 14():1186478. PubMed ID: 37529048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.
    Ondondo B; Murakoshi H; Clutton G; Abdul-Jawad S; Wee EG; Gatanaga H; Oka S; McMichael AJ; Takiguchi M; Korber B; Hanke T
    Mol Ther; 2016 Apr; 24(4):832-42. PubMed ID: 26743582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
    Hancock G; Morón-López S; Kopycinski J; Puertas MC; Giannoulatou E; Rose A; Salgado M; Hayton EJ; Crook A; Morgan C; Angus B; Chen F; Yang H; Martinez-Picado J; Hanke T; Dorrell L
    J Int AIDS Soc; 2017 May; 20(1):21171. PubMed ID: 28537062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.
    Abdul-Jawad S; Ondondo B; van Hateren A; Gardner A; Elliott T; Korber B; Hanke T
    Mol Ther; 2016 Feb; 24(2):375-384. PubMed ID: 26581160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.
    Wee EG; Moyo NA; Saunders KO; LaBranche C; Donati F; Capucci S; Parks R; Borthwick N; Hannoun Z; Montefiori DC; Haynes BF; Hanke T
    Mol Ther Methods Clin Dev; 2019 Sep; 14():148-160. PubMed ID: 31367651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design.
    Kunwar P; Hawkins N; Dinges WL; Liu Y; Gabriel EE; Swan DA; Stevens CE; Maenza J; Collier AC; Mullins JI; Hertz T; Yu X; Horton H
    PLoS One; 2013; 8(5):e64405. PubMed ID: 23741326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.
    Li F; Finnefrock AC; Dubey SA; Korber BT; Szinger J; Cole S; McElrath MJ; Shiver JW; Casimiro DR; Corey L; Self SG
    PLoS One; 2011; 6(6):e20479. PubMed ID: 21695251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.
    Zou C; Murakoshi H; Kuse N; Akahoshi T; Chikata T; Gatanaga H; Oka S; Hanke T; Takiguchi M
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
    Hartnell F; Brown A; Capone S; Kopycinski J; Bliss C; Makvandi-Nejad S; Swadling L; Ghaffari E; Cicconi P; Del Sorbo M; Sbrocchi R; Esposito I; Vassilev V; Marriott P; Gardiner CM; Bannan C; Bergin C; Hoffmann M; Turner B; Nicosia A; Folgori A; Hanke T; Barnes E; Dorrell L
    Front Immunol; 2018; 9():3175. PubMed ID: 30713538
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.
    Moyo N; Borthwick NJ; Wee EG; Capucci S; Crook A; Dorrell L; Hanke T
    PLoS One; 2017; 12(7):e0181382. PubMed ID: 28719652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.
    Ahmed T; Borthwick NJ; Gilmour J; Hayes P; Dorrell L; Hanke T
    Vaccine; 2016 Feb; 34(9):1215-24. PubMed ID: 26784683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
    Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
    J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.
    Santra S; Liao HX; Zhang R; Muldoon M; Watson S; Fischer W; Theiler J; Szinger J; Balachandran H; Buzby A; Quinn D; Parks RJ; Tsao CY; Carville A; Mansfield KG; Pavlakis GN; Felber BK; Haynes BF; Korber BT; Letvin NL
    Nat Med; 2010 Mar; 16(3):324-8. PubMed ID: 20173754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8
    Murakoshi H; Zou C; Kuse N; Akahoshi T; Chikata T; Gatanaga H; Oka S; Hanke T; Takiguchi M
    Retrovirology; 2018 Jul; 15(1):46. PubMed ID: 29970102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Reactive CD8 T-Cell Responses Elicited by Adenovirus Type 5-Based HIV-1 Vaccines Contributed to Early Viral Evolution in Vaccine Recipients Who Became Infected.
    Boppana S; Fiore-Gartland A; Bansal A; Goepfert P
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31645444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials.
    Hanke T
    Expert Rev Vaccines; 2019 Oct; 18(10):1029-1041. PubMed ID: 31613649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.